265 related articles for article (PubMed ID: 4550085)
1. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA
N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085
[No Abstract] [Full Text] [Related]
2. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
[No Abstract] [Full Text] [Related]
3. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
Klawans HL; Ringel SP
Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
[No Abstract] [Full Text] [Related]
4. Interaction between levodopa and methyldopa.
Gibberd FB; Small E
Br Med J; 1973 Apr; 2(5858):90-1. PubMed ID: 4573316
[TBL] [Abstract][Full Text] [Related]
5. Modification of levodopa effect by systemic decarboxylase inhibition.
Mars H
Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
[No Abstract] [Full Text] [Related]
6. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Court J; Kase JC; Mena I; Palacios E
Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
[No Abstract] [Full Text] [Related]
7. Levodopa in the treatment of Parkinsonism.
Cotzias GC
JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
[No Abstract] [Full Text] [Related]
8. MK 486 and levodopa in treatment of Parkinsonism.
Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
[No Abstract] [Full Text] [Related]
9. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
Sweet RD; Lee JE; McDowell F
Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
[No Abstract] [Full Text] [Related]
10. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
Bianchine JR; Messiha FS; Hsu TH
Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
[No Abstract] [Full Text] [Related]
11. Modification of Parkinsonism--chronic treatment with L-dopa.
Cotzias GC; Papavasiliou PS; Gellene R
N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
[No Abstract] [Full Text] [Related]
12. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
Fahn S
Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
[No Abstract] [Full Text] [Related]
13. Levodopa.
Lancet; 1971 Sep; 2(7723):533. PubMed ID: 4105672
[No Abstract] [Full Text] [Related]
14. Pyridoxine, DOPA, and Parkinsonism.
Yahr MD; Duvoisin RC; Côté L; Cohen G
Adv Biochem Psychopharmacol; 1972; 4():185-94. PubMed ID: 4555927
[No Abstract] [Full Text] [Related]
15. Synergism of levodopa by alpha methyldopa.
Fermaglich J; O'Doherty DS
Trans Am Neurol Assoc; 1971; 96():231-4. PubMed ID: 5159089
[No Abstract] [Full Text] [Related]
16. [10 years of L-DOPA therapy of Parkinson's syndrome].
Birkmayer W
Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
[No Abstract] [Full Text] [Related]
17. Parkinsonism and DOPA.
Cotzias GC; Papavasiliou PS; Gellene R; Aronson RB
Trans Assoc Am Physicians; 1968; 81():171-83. PubMed ID: 4889342
[No Abstract] [Full Text] [Related]
18. L-dopa therapy in parkinsonism: mechanism of action.
Sandler M
Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
[No Abstract] [Full Text] [Related]
19. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
Wälzholz U; Schönfelder H
Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
[No Abstract] [Full Text] [Related]
20. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
[Next] [New Search]
